Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale

Innovations in Clinical Neuroscience

Volumn 9, Issue 1, 2012, Pages 15-24

  Allen, Michael H ^a   Daniel, David G ^b   Revicki, Dennis A ^b   Canuso, Carla M ^c   Turkoz, Ibrahim ^c   Fu, Dong Jing ^c   Alphs, Larry ^c   Jack Ishak, K ^d   Bartko, John J ^e   Lindenmayer, Jean Pierre ^f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d UNITED BIOSOURCE CORPORATION   (Canada)

^e Independent consultant ^*  (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Methodolog; Psychometrics; Schizoaffective disorder

Indexed keywords

PALIPERIDONE; PLACEBO;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTENT VALIDITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; EFFECT SIZE; HUMAN; INTERMETHOD COMPARISON; INTERRATER RELIABILITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROCESS DEVELOPMENT; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYMPTOMATOLOGY; TEST RETEST RELIABILITY; TREATMENT DURATION; TREATMENT RESPONSE; VALIDITY; YOUNG MANIA RATING SCALE;

EID: 84857282079     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cheniaux E, Landeira-Fernandez J, Lessa TL, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Discord. 2008;106:209-217.
2. Harrow M, Grossman LS, Herbener ES, Davies EW. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421-426.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
4. Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatric Diseases and Treatment. 2008;4:1089-1109.
5. Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull. 2009;35:482-490.
6. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
7. Lindenmayer JP, Kay SR, Van Praag H. Distinction of schizoaffective from schizophrenic profile: independent validation. Schizophr Res. 1989;2:423-424.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
10. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
11. Addington D, Addington J, Maticka- Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11:239-244.
12. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGIBP. Psychiatry Res. 1997;73:159-171.
13. Lehmann E. Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsychiatry. 1984;17:71-75.
14. Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology. 2006;31:406-412.
15. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology (028 Clinical Global Impressions [CGI]). Rockville, MD: National Institutes of Health, 1976:218-222.
17. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression- Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003:16-23.
18. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71:587-598.
19. Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol. 2010;30:487-495.
20. Hays R, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays R (eds). Assessing Quality of Life in Clinical Trials, Second Edition. New York, NY: Oxford University Press; 2005:25-40.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences, Second Edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
22. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231-238.
23. Price LR, Lurie A, Wilkins C. Computer program exchange: EQUIPERCENT: a SAS program for calculating equivalent scores using the equipercentile method. Appl Psychological Meas. 2001;25:332. DOI 10.1177/01466210122032172.
24. Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98:318-322.